Compare HubSpot Inc (HUBS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs BIO-TECHNE Corp — how do they compare? HubSpot Inc trades at $231.12 (market cap $11.56B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: HubSpot Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and BIO-TECHNE Corp for 63 Days on average.
| HUBS | TECH | |
|---|---|---|
Market Cap | $11.56B | $11.36B |
Volume | 1,891,287 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $494.58 | $72.61 |
52-Week Low | $170.39 | $43.31 |
Typical Hold Time | 78 Days | 63 Days |
Enterprise Value | $10.46B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $220.31, up 1.55% on the day, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $1.7B in 2022 to $3.1B in 2025, while net income turned positive in 2024. Recent news highlights an AI-focused strategy unveiled at Analyst Day and a deepened partnership with OpenAI, targeting margin expansion and SMB growth.
The outlook is cautiously optimistic, with a consensus price target of $243.65 implying ~11% upside. Key opportunities include sustained revenue growth, margin improvement, and AI integration, but risks involve high valuation multiples (P/E 78.39), competitive pressures, and insider selling. Wall Street sentiment is bullish (57% buy ratings), though technical indicators suggest near-term resistance.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
